Anti-HIV agents. Vicriviroc: is the risk of cancer increased?
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006689:Hodgkin Disease / Q000209:etiology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000209:etiology; D013274:Stomach Neoplasms / Q000209:etiology
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D010879:Piperazines; D011743:Pyrimidines; C486781:vicriviroc